In addition to reauthorizing the statutorily defined user fees that pharmaceutical and medical-device manufacturers pay when applying for FDA approval of new products, the FDA Safety and Innovation Act streamlines the process of the premarketing review of drugs and devices.
No takes yet. Share an insight, caveat, or question.
Kramer et al. (2012) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: